Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 901–999 of 999
Joo, H. J., Hong, S. J., Yu, C. W., Shin, S. Y., & Kim, E. J. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.06.036 · Cited by 2
Jung, M., Cho, D., Choi, J., Kim, M., Lee, C. J., Son, J., Kim, Y., Youn, J., & Yoo, B. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15359 · Cited by 2
Kalogeropoulos, A. P., Hameed, I., Anker, S. D., Bayés‐Genís, A., Böhm, M., Budden, J. J., Cleland, J. G. F., Coats, A. J. S., Ezekowitz, J. A., Filippatos, G. S., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3754 · Cited by 1
Chan, P.-K., Hsu, C., Lee, C.-C., Yu, F.-H., Chung, F., Liao, C., Huang, J., Liang, H.-W., Lee, Y., Lin, P.-L., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1620266 · Cited by 1
Iacoviello, M., Sarullo, F. M., Bilato, C., Correale, M., Gesaro, G. D., Driussi, M., Passantino, A., Villani, A., & Lenarda, A. D. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.39 · Cited by 1
Cheng, C., Nie, Y., Chen, D., Yang, Y., Liang, S., & Yu, Q. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1550624 · Cited by 1
Bonini, N., Mantovani, M., Vitolo, M., Serafini, K., Tartaglia, E., Rampini, F., Grossule, F., Cherubini, B., Mastronardi, M. L., Trapanese, P., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12090328 · Cited by 1
Hsu, W., Shiau, B.-W., Wu, J., Chuang, M., Tsai, Y., Huang, P., Hu, K.-C., Hsu, W., Liu, T., Liao, K., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01140-x · Cited by 1
McDonald, M. A., Kok, M., Ducharme, A., Ezekowitz, J. A., Howlett, J. G., Rojas‐Fernandez, C. H., & Udell, J. A. (2025) · CJC Open · doi:10.1016/j.cjco.2025.10.007 · Cited by 1
Green, C. L., Aladesanmi, O., Chery, G. S., Jackson, L. R., & Thomas, K. L. (2025) · Journal of the National Medical Association · doi:10.1016/j.jnma.2025.11.005 · Cited by 1
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.12.003 · Cited by 2
Nagahiro, T., Konishi, M., Kikkoji, E., Fukushima, Y., Matsuzawa, Y., Sato, R., Okuda, J., Sawada, R., Tsukahara, K., Takano, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02501-8 · Cited by 1
Guideline-Directed Medical Therapy in Heart Failure: The Need for Speed
Karam, A., & Aranda, J. M. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2025.0042 · Cited by 1
Design, Rationale, and Methods of the INITIATE-HFrEF Trial
Ferreira, J. P., Oliveira, A. S., Saraiva, F. S., Pereira-Sousa, I., Azevedo, R., Angélico‐Gonçalves, A., Grijó, C. M. S. P. M., Santos, M. P., Gavina, C., Santos, M., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102589 · Cited by 1
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.02.035 · Cited by 2
Bleeding disorder, a newly recognized adverse event following sacubitril/valsartan therapy
Al-Omari, Y., Mustafa, S., Saleh, A., & Abdel-Razaq, W. S. (2026) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2026_006178 · Cited by 1
Gupta, D. K., Stevenson, L. W., Garner, E. M., Maulion, C., Nian, H., Wright, P. R., Turcu, A. F., Wei, S., & Brown, N. J. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.014117 · Cited by 1
Radić, M., Jurin, I., Rode, F., Šimunović, L., Kolundžić, P., Hadžibegović, I., Manola, Š., Vitlov, P., Mihajlović, V. I., Grizelj, D., et al. (2026) · Medicina · doi:10.3390/medicina62061017 · Cited by 1
Laborante, R., Bianchini, E., Beer, B. N., Valente, V., Mavridis, D., Bidino, R. D., D’Amario, D., Roes, K. C. B., Mol, P. G. M., Basile, C., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag233 · Cited by 2
Subclinical hypotension in acute decompensated heart failure: prognosis and treatment implementation
Savonitto, G., Stolfo, D., Biber, M. E., Cocianni, D., Contessi, S., Perotto, M., Rizzi, J. G., Soranzo, E., Masè, M., Merlo, M., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107080 · Cited by 1
Inicio del sacubitrilo-valsartán en pacientes hospitalizados frente a ambulatorios en la vida real
Ruíz, M. G., Girón, M. F. D. S., Singh, M., Marco, M. D. V. G., Dorta, E. C., & Quintana, A. G. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.01.016 · Cited by 1
Trullàs, J. C., Formiga, F., Casado, J., & Franco, Á. G. (2019) · Revista Clínica Española · doi:10.1016/j.rce.2019.05.009 · Cited by 1
Highlights of AHA Scientific Sessions 2019: novel approaches in cardiovascular risk reduction
Akoumianakis, I. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz319 · Cited by 1
LCZ696 (sacubitril/valsartan) for patients with heart failure
Hernández, A. V., Pasupuleti, V., Banach, M., & Bielecka-Dabrowa, A. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013517 · Cited by 1
Ling, H., Patel, N., & Egolum, U. O. (2020) · Hospital Pharmacy · doi:10.1177/0018578720946756 · Cited by 1
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients
Rerick, L., Elston, C. A., Kester, J., Montepara, C. A., & Gengler, B. E. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000966 · Cited by 1
Eyyubova, U. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4491 · Cited by 1
Gan, H., Tang, H. Y., Huang, Y., Wang, D., Pu, P., & Zuo, Z. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203069 · Cited by 1
Acute decompensated heart failure. What has changed in the clinical guidelines in 2021?
Жиров, И. В., Николаевна, Н. С., Khalilova, U. A., Osmolovskaya, Y. F., Алексеевна, Ж. И., Рашитович, Г. Р., Chaikovskaia, O. I., Reitblat, O. M., Prints, I. S., Кочетов, А. Г., et al. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.1.201410 · Cited by 1
Trullàs, J. C., Formiga, F., Casado, J., & González-Franco, A. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.05.006 · Cited by 1
Baldetti, L., Gallone, G., Sacchi, S., Pazzanese, V., Gramegna, M., Calvo, F., Boccellino, A., Ajello, S., Scandroglio, A. M., & Cappelletti, A. M. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.009 · Cited by 1
Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction
Moloce, M.-A., Costache, I. I., Nicolae, A., & Aursulesei, V. O. (2022) · Life · doi:10.3390/life12081112 · Cited by 1
Whiteside, H. L., Hillerson, D., Buescher, V., Kreft, K., Mayer, K. P., Montgomery-Yates, A. A., & Gupta, V. A. (2022) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000294 · Cited by 4
Málek, F., & Táborský, M. (2022) · Cor et Vasa · doi:10.33678/cor.2022.079 · Cited by 1
吴, 祎. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121626 · Cited by 1
Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?
Nechita, A. C. (2022) · Romanian Journal of Cardiology · doi:10.2478/rjc-2022-0035 · Cited by 1
Europäische Leitlinien Herzinsuffizienz: medikamentöse Therapie
Grundmann, S., & Mühlen, C. V. Z. (2023) · Herz · doi:10.1007/s00059-022-05157-z · Cited by 2
Hafizullah, M., Aman, W., & Afridi, H. (2023) · Pakistan Heart Journal · doi:10.47144/phj.v56i1.2454 · Cited by 2
Chopra, H. K., Wander, G. S., Ponde, C. K., Nanda, N. C., Khullar, D., Venugopal, K., Ray, S., Nair, T., Rana, D. S., Kher, V., et al. (2023) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0209 · Cited by 1
Kobalava, Z. D., & Назаров, И. С. (2023) · Kardiologiia · doi:10.18087/cardio.2023.3.n2418 · Cited by 1
dos Santos, R. C., da Silva, A. P. P., de Menezes, A. L. F., Queiroga, C. G., Lima, D. D. S. O., Bezerra, D. N., Cavalcante, D. S., Silva, F., de Vasconcelos, G. G., & de Oliveira, R. C. (2024) · Seven Editora eBooks · doi:10.56238/medfocoexplconheci-046 · Cited by 1
Hu, J., Schwann, A. N., Tan, J. W., Nuqali, A., Riello, R. J., & Beasley, M. (2023) · Cardiology Clinics · doi:10.1016/j.ccl.2023.06.007 · Cited by 3
Kolesnikova, E. V., Myachina, O. V., & Pashkov, A. N. (2023) · Cardiosomatics · doi:10.17816/cs456434 · Cited by 2
Pepe, G., Vignani, M., Casolo, G., Sanna, M., & Ghiadoni, L. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad150 · Cited by 1
Matta, A. G., Ohlmann, P., Nader, V., Levai, L., Kang, R., Carrié, D., & Roncalli, J. G. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102347 · Cited by 1
Meyer-Jens, M., Wenzel, K., Grube, K., Rüdebusch, J., Krämer, E., Bahls, M., Müller, K., Voß, H., Schlüter, H., Felix, S. B., et al. (2024) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2023.100059 · Cited by 6
Almansouri, N. E., Bakkannavar, S., Faheem, Y. A. M., Jaiswal, A., Shergill, K., Boppana, K., & Nath, T. S. (2024) · Cureus · doi:10.7759/cureus.54501 · Cited by 1
DESAFIOS E AVANÇOS NA ABORDAGEM DA INSUFICIÊNCIA CARDÍACA COM FRAÇÃO DE EJEÇÃO REDUZIDA
Wollmann, C. A. R., Freire, E. M., de Almeida, E. B., de Camargo, G. L., Filho, G. S. L. S., Borges, H. D. S., Ferreira, P. C. D. L., & Faria, T. M. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p603 · Cited by 2
Chang, T.-W., Hung, C., Ko, S.-L., Liao, C., Hsu, C., Huang, N., Mebazaa, A., & Chang, H.-Y. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.05.015 · Cited by 1
Pasquale, C. G. D., Claggett, B. L., Jering, K., McMurray, J. J. V., Mann, D. L., Miao, Z. M., Granger, C. B., Køber, L., Maggioni, A. P., Rouleau, J. L., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.011393 · Cited by 1
Gestion périopératoire des nouveaux traitements médicamenteux de l’insuffisance cardiaque
Delignette, M., Chaffard, C., Orion, M., & Blet, A. (2024) · Le Praticien en Anesthésie Réanimation · doi:10.1016/j.pratan.2024.09.003 · Cited by 1
Kuan, W.-C., Lim, K. K., Chee, K. H., Kasim, S. S., Dujaili, J. A., Lee, K. K. C., & Teoh, S. L. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03818-6 · Cited by 3
Sodium-glucose co-transporter 2 inhibitors in acute heart failure: What are you waiting for?
Morillas, H., & Colet, J. C. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.03.002 · Cited by 1
Eschenhagen, T., & Weil, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_7 · Cited by 2
Oh, B.-C., Cho, D., Choi, J., Kwon, S., & Yoo, B. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2024.0403 · Cited by 1
Valsartan/Sacubitril ist auch bei dekompensierter Herzinsuffizienz sicher und effektiv
Overbeck, P. (2018) · CardioVasc · doi:10.1007/s15027-018-1461-5 · Cited by 1
Aktuelles zur evidenzbasierten medikamentösen Herzinsuffizienztherapie
Emrich, I. E., Wintrich, J., Kindermann, I., & Böhm, M. (2019) · Herz · doi:10.1007/s00059-019-4827-2 · Cited by 1
Early Implementation of Sacubitril/Valsartan for Patients With Heart Failure
Wilcox, J. E. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4822 · Cited by 1
Burning issues in acute heart failure management
Ker, J. A., & Outhoff, K. (2019) · South African Family Practice · doi:10.4102/safp.v61i6.5063 · Cited by 1
Update Therapie der Herzinsuffizienz 2019
Pauschinger, M., Laufs, U., & Frey, N. (2020) · Der Kardiologe · doi:10.1007/s12181-020-00390-4 · Cited by 1
Design and Synthesis of an Aniline Derivative with Biological Activity on Heart Failure
Alejandra, G. E., Lauro, F., Marcela, R., Maria, L., Francisco, D.-C., Virginia, M., & Yazmin, O. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200709163008 · Cited by 1
Acute decompensation of chronic heart failure and renal dysfunction. Diagnosis and treatment
Glizer, S. L., Анатольевич, Ш. О., & Петрова, М. М. (2020) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2020-35-2-35-43 · Cited by 1
ACEi/ARB naif hastalarda sakubitril/valsartan başlanabilir mi?
Çelik, A. (2020) · Updates in Cardiology · doi:10.5543/ucard.2020.10820 · Cited by 1
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease
Tamargo, J. L., Caballero, R., & Delpón, E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1891223 · Cited by 1
Lo scompenso cardiaco a 360 gradi
Gnerre, G. E. P., & Pasquale, G. D. (2021) · Italian Journal of Medicine · doi:10.4081/itjm.q.2021.2 · Cited by 2
Checklist para A Pré-Alta de Internamento por Insuficiência Cardíaca
Bettencourt, P., Pimenta, J. M., Araújo, I., Marques, I., Lourenço, C., & Sarmento, P. (2021) · Medicina Interna · doi:10.24950/neic/184/20/1/2021 · Cited by 1
Esteban‐Fernández, A., Vicent, L., Díez‐Villanueva, P., Gómez-Bueno, M. F., Bover, R., Bagudá, J. D. J., Iniesta, Á. M., Ayesta, A., & Martínez‐Sellés, M. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2021.12.001 · Cited by 1
de Polavieja, J. I. M. G., Sigismondi, A., Cruces, S. O., Ríos, E., Aguilar, J. R. L., Sánchez, A. J. M., Suárez, A. L., & Fernández, J. F. D. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2021.12.005 · Cited by 1
Heart Failure with Reduced Ejection Fraction
Rao, P., & Sabe, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-88953-1_15 · Cited by 1
Sacubitril/valsartan: A practical guide revisited
Fonseca, C., Brito, D. A., Ferreira, J., Franco, F., Morais, J., & Silva‐Cardoso, J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.05.023 · Cited by 1
Kardiorenales Syndrom: Herz- und Niereninsuffizienz gleichzeitig im Fokus
Schwenger, V., Latus, J., Mahfoud, F., & Remppis, B. A. (2022) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2022.06.17.01 · Cited by 1
Bastać, D., Joksimović, Z., Pavlović, S., Bastać, M., Raščanin, A., & Đorđioski, I. (2022) · Timocki medicinski glasnik · doi:10.5937/tmg2201040b · Cited by 2
Zhang, X., Yang, S., & Xu, Z. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/4298644 · Cited by 1
RetractedCancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan
Hu, F., Yu, H., Du, W., Chen, L., Su, J., & Chen, X. (2023) · Cardiology Plus · doi:10.1097/cp9.0000000000000056
The Other Serelaxin in Acute Heart Failure Study: Lessons from a Pragmatic Clinical Trial
Kalogeropoulos, A. P., & Butler, J. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1416 · Cited by 1
Packer, M. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz281 · Cited by 1
Ambrosy, A. P., DeVore, A. D., & Velazquez, E. J. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1540 · Cited by 1
Self-citationSacubitril/valsartan: A practical guide revisited
Fonseca, C., Brito, D. A., Ferreira, J., Franco, F., Morais, J., & Silva‐Cardoso, J. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.05.007 · Cited by 1
DeVore, A. D., & Hernandez, A. F. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.09.010 · Cited by 1
Self-citationRivas‐Lasarte, M., Garcia, J. A., Mirabet, S., Sionís, A., Roig, E. S., & Juan Cinca, A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1719 · Cited by 1
The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value?
Yancy, C. W., Hernandez, A. F., & Bonow, R. O. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.3108 · Cited by 1
Consider Everything When Prescribing Sacubitril/Valsartan
Gottlieb, S. S., & Ahmed, T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.090 · Cited by 1
Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan
Gillette, M., & Bozkurt, B. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020964923 · Cited by 4
Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?
Buono, M. G. D., Damonte, J. I., Trankle, C. R., Bhardwaj, H. L., Markley, R., Turlington, J., Tassell, B. W. V., Salloum, F. N., & Abbate, A. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001103 · Cited by 1
Aimo, A., Castiglione, V., & Bayés‐Genís, A. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2580 · Cited by 1
Sacubitril/Valsartan in Advanced Heart Failure
Samsky, M. D., & Sen, S. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.05.011 · Cited by 1
Ali, A., & Ortega–Legaspi, J. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-1073 · Cited by 1
Ahmed, H. N. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.10.035 · Cited by 1
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendera, K., Taha, A., Nadarajah, R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116096 · Cited by 1
Management of Acute Heart Failure
Means, G. T., & Katz, J. N. (2017) · Springer eBooks · doi:10.1007/978-3-319-43341-7_11
Baka, T., Stanko, P., Hrenak, J., Dukát, A., & Šimko, F. (2021) · Cardiology letters · doi:10.4149/cardiol_2021_1_5
A review of interventions to improve clinical outcomes following hospitalisation for heart failure
Spall, H. G. C. V., & Mamas, M. A. (2019) · Kardiologia Polska · doi:10.5603/kp.a2019.0039 · Cited by 2
Rodrigues, G., Tralhão, A., Aguíar, C., Freitas, P., Ventosa, A., & Mendes, M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.02.001
Highlights from the 2018 American Heart Association Scientific Sessions in Chicago, Illinois
Steen, D. L. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01831-y
ARNI auch bei akut dekompensierter Herzinsuffizienz erfolgreich
Holzgreve, H. (2019) · CardioVasc · doi:10.1007/s15027-019-1545-x
Editorial commentary: Acute heart failure: A patient's curse or a provider's opportunity?
Krim, S. R. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.04.004
Navigating Your Acute Heart Failure Patient in Emergency and Pre-Discharge Phase
Setianto, B. Y. (2019) · ACI (Acta Cardiologia Indonesiana) · doi:10.22146/aci.47680
Grigg, S. E. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2019-111260
Sacubitril / valsartán: nueva opción terapeútica en insuficiencia cardíaca
Montealegre, S. M. F., Muñoz, M. F. M., & Álvarez, A. D. P. (2019) · Revista Medica Sinergia · doi:10.31434/rms.v4i11.297 · Cited by 2
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.